MedTrace Logo

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

NCT06604442 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-05-12

Study results available
· View outcomes & findings →

Summary

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Conditions

Interventions

DRUG

flotufolastat (18F)

Positron emission tomography (PET)

DRUG

piflufolastat (18F)

Positron emission tomography (PET)

Sponsors & Collaborators

  • Aixial Group

    collaborator INDUSTRY

  • Blue Earth Diagnostics

    lead INDUSTRY

Principal Investigators

  • Brian Helfand, M.D. · Endeavor Health NorthShore Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2025-08-29
Completion
2025-08-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06604442 on ClinicalTrials.gov